{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T19:58:55Z","timestamp":1765742335960,"version":"3.46.0"},"reference-count":22,"publisher":"BMJ","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pathol"],"published-print":{"date-parts":[[1998,7]]},"abstract":"<jats:p>AIM: To examine sera for the presence of salicylic acid and 2,3- and 2,5-dihydroxybenzoic acids (2,3- and 2,5-DHBA), in individuals not taking salicylate drugs. METHODS: Extracts of acidified serum samples were analysed by high performance liquid chromatography with electro-chemical detection. The chromatographic conditions were altered, and the retention times of the unknown compounds compared against authentic salicylic acid, 2,3-DHBA, and 2,5-DHBA. Serum samples (some spiked with salicylic acid) were incubated with salicylate hydroxylase and analyses undertaken. An extract of acidified serum was derivatised using N-methyl-N-trimethylsilyltrifluoroacetamide and the salicylic acid derivative identified by gas chromatography-mass spectrometry. RESULTS: Salicylic acid, 2,3-DHBA, and 2,5-DHBA were identified as being normal constituents of serum. CONCLUSIONS: Salicylic acid, 2,3-DHBA, and 2,5-DHBA possess anti-inflammatory properties. The finding that these compounds are present as normal constituents of serum, possibly arising from diet, raises important questions as to their role in the promotion of health.<\/jats:p>","DOI":"10.1136\/jcp.51.7.502","type":"journal-article","created":{"date-parts":[[2008,12,31]],"date-time":"2008-12-31T19:05:02Z","timestamp":1230750302000},"page":"502-505","source":"Crossref","is-referenced-by-count":27,"title":["The identification of salicylates as normal constituents of serum: a link between diet and health?"],"prefix":"10.1136","volume":"51","author":[{"given":"J R","family":"Paterson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Blacklock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Wiles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J R","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[1998,7,1]]},"reference":[{"key":"ref_1","first-page":"124","article-title":"The aspirin story. In: The conquest of pain","author":"Fairley, P.","year":"1978","unstructured":"Fairley P. The aspirin story. In: The conquest of pain. London: Michael Joseph, 1978:124\u201367."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet treatment. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","author":"Collaboration, Antiplatelet Trialists","year":"1994","unstructured":"Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet treatment. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81\u2013106.","journal-title":"BMJ"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/ssu.2980100303","article-title":"Aspirin and the prevention of colorectal cancer: a review of the evidence","volume":"10","author":"Paganini-Hill, A.","year":"1994","unstructured":"Paganini-Hill A. Aspirin and the prevention of colorectal cancer: a review of the evidence. Semin Surg Oncol 1994;10:158\u201364.","journal-title":"Semin Surg Oncol"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1056\/NEJM199509073331011","article-title":"Aspirin as the prophylaxis against colorectal cancer","volume":"333","author":"Marcus, A.J.","year":"1995","unstructured":"Marcus AJ. Aspirin as the prophylaxis against colorectal cancer. N Engl J Med 1995;333:656\u20138.","journal-title":"N Engl J Med"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1749-6632.1971.tb46905.x","article-title":"Salicylate metabolism in man","volume":"179","author":"Davison, C.","year":"1971","unstructured":"Davison C. Salicylate metabolism in man. Ann N Y Acad Sci 1971;179:249\u201368.","journal-title":"Ann N Y Acad Sci"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1073\/pnas.84.5.1417","article-title":"Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity","volume":"84","author":"Higgs, G.A.; Salmon, J.A.; Henderson, B.","year":"1987","unstructured":"Higgs GA, Salmon JA, Henderson B, et al. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity. Proc Natl Acad Sci USA 1987;84:1417\u201320.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref_7","first-page":"2273","article-title":"DiVerential growth inhibition by the aspirin metabolite salicylate in human colorectal tumour cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma cell lines","volume":"56","author":"Elder, D.J.E.; Hague, A.; Hicks, D.J.","year":"1996","unstructured":"Elder DJE, Hague A, Hicks DJ, et al. DiVerential growth inhibition by the aspirin metabolite salicylate in human colorectal tumour cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma cell lines. Cancer Res 1996;56:2273\u20136.","journal-title":"Cancer Res"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0378-4347(93)E0381-Y","article-title":"Direct gradient reversed-phase high-performance liquid chromatographic determination of salicylic acid, with the corresponding glycine and glucuronide conjugates in human plasma and urine","volume":"652","author":"Vree, T.B.; van Ewijk-Beneken Kolmer, E.W.J.; CPWGM, Verwey-van Wissen","year":"1994","unstructured":"Vree TB, van Ewijk-Beneken Kolmer EWJ, Verwey-van Wissen CPWGM, et al. Direct gradient reversed-phase high-performance liquid chromatographic determination of salicylic acid, with the corresponding glycine and glucuronide conjugates in human plasma and urine. J Chromatogr B 1994;652:161\u201370.","journal-title":"J Chromatogr B"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/chromsci\/34.4.166","article-title":"Rapid highperformance liquid chromatographic assay for salicylic acid in plasma without solvent extraction","volume":"34","author":"Coudray, C.; Mangournet, C.; Bouhadjeb, S.","year":"1996","unstructured":"Coudray C, Mangournet C, Bouhadjeb S, et al. Rapid highperformance liquid chromatographic assay for salicylic acid in plasma without solvent extraction. J Chromatogr Sci 1996;34:166\u201373.","journal-title":"J Chromatogr Sci"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/jnci\/89.15.1152","article-title":"Suppression of human colorectal mucosal prostaglandins: determining the lowest eVective aspirin dose","volume":"89","author":"RuYn, M.T.; Krishnan, K.; Rock, C.L.","year":"1997","unstructured":"RuYn MT, Krishnan K, Rock CL, et al. Suppression of human colorectal mucosal prostaglandins: determining the lowest eVective aspirin dose. J Natl Cancer Inst 1997;89: 1152\u201360.","journal-title":"J Natl Cancer Inst"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1021\/jf950458y","article-title":"Determination of acetylsalicylic acid and salicylic acid in foods, using HPLC with fluorescence detection","volume":"44","author":"Venema, D.P.; Hollman, P.C.H.; KPLTM, Janssen","year":"1996","unstructured":"Venema DP, Hollman PCH, Janssen KPLTM, et al. Determination of acetylsalicylic acid and salicylic acid in foods, using HPLC with fluorescence detection. J Agric Food Chem 1996;44:1762\u20137.","journal-title":"J Agric Food Chem"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0006-2952(88)90729-0","article-title":"2,3-Dihydroxybenzoic acid is a product of human aspirin metabolism","volume":"37","author":"Grootveld, M.; Halliwell, B.","year":"1988","unstructured":"Grootveld M, Halliwell B. 2,3-Dihydroxybenzoic acid is a product of human aspirin metabolism. Biochem Pharmacol 1988;37:271\u201380.","journal-title":"Biochem Pharmacol"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(94)92550-X","article-title":"Take two glasses of wine and see me in the morning","volume":"343","author":"Muller, C.J.; Fugelsang, K.C.","year":"1994","unstructured":"Muller CJ, Fugelsang KC. Take two glasses of wine and see me in the morning. Lancet 1994;343:1428\u20139.","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/ajcn\/64.5.743","article-title":"Urinary salicylate excretion in subjects eating a variety of diets shows that amounts of bioavailable salicylates in food are low","volume":"64","author":"KPLTM, Janssen; PCH, Hollman; E, Reichman","year":"1996","unstructured":"Janssen KPLTM, Hollman PCH, Reichman E, et al. Urinary salicylate excretion in subjects eating a variety of diets shows that amounts of bioavailable salicylates in food are low. Am J Clin Nutr 1996;64:743\u20137.","journal-title":"Am J Clin Nutr"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker, P.M.; Cushman, M.; Stampfer, M.J.","year":"1997","unstructured":"Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973\u20139.","journal-title":"N Engl J Med"},{"key":"ref_16","first-page":"393","article-title":"Prostaglandin endoperoxide synthase: why two isoforms?","volume":"33","author":"Williams, C.S.; Dubois, R.N.","year":"1996","unstructured":"Williams CS, Dubois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol 1996;270 (Gastrointest Liver Physiol 33):G393\u2013400.","journal-title":"Am J Physiol"},{"key":"ref_17","first-page":"2556","article-title":"Expression of prostaglandin G\/H synthase-1 and -2 protein in human colon cancer","volume":"55","author":"Kargman, S.L.; O\u2019Neill, G.P.; Vickers, P.J.","year":"1995","unstructured":"Kargman SL, O\u2019Neill GP, Vickers PJ, et al. Expression of prostaglandin G\/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995;55:2556\u20139.","journal-title":"Cancer Res"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1073\/pnas.88.6.2384","article-title":"Aspirin inhibits interleukin 1-induced prostaglandin H synthase expression in cultured endothelial cells","volume":"88","author":"Wu, K.W.; Sanduja, R.; Tsai, A.-L.","year":"1991","unstructured":"Wu KW, Sanduja R, Tsai A-L, et al. Aspirin inhibits interleukin 1-induced prostaglandin H synthase expression in cultured endothelial cells. Proc Natl Acad Sci USA 1991; 88:2384\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0031-6997(25)06634-7","article-title":"Drugs which inhibit prostaglandin biosynthesis","volume":"26","author":"Flower, R.J.","year":"1974","unstructured":"Flower RJ. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev 1974;26:33\u201367.","journal-title":"Pharmacol Rev"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/0005-2760(75)90181-2","article-title":"Some characteristics of the prostaglandin synthesizing system in rabbit kidney microsomes","volume":"398","author":"Blackwell, G.J.; Flower, R.J.; Vane, JR","year":"1975","unstructured":"Blackwell GJ, Flower RJ, Vane JR. Some characteristics of the prostaglandin synthesizing system in rabbit kidney microsomes. Biochim Biophys Acta 1975;398:178\u201390.","journal-title":"Biochim Biophys Acta"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF01975714","article-title":"Is aspirin a prodrug for antioxidant and cytokine-modulating oxymetabolites?","volume":"39","author":"Haynes, D.R.; Wright, P.F.A.; Gadd, S.J.","year":"1993","unstructured":"Haynes DR, Wright PFA, Gadd SJ, et al. Is aspirin a prodrug for antioxidant and cytokine-modulating oxymetabolites? Agents Actions 1993;39:49\u201358.","journal-title":"Agents Actions"},{"key":"ref_22","first-page":"90","article-title":"Antioxidant vitamins, cancer and cardiovascular disease","volume":"1189","author":"Greenberg, E.R.; Sporn, M.B.","year":"1996","unstructured":"Greenberg ER, Sporn MB. Antioxidant vitamins, cancer and cardiovascular disease. N Engl J Med 1996;334;1189\u2013 90.","journal-title":"N Engl J Med"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp.51.7.502","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T05:44:27Z","timestamp":1764999867000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp.51.7.502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,7]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[1998,7,1]]},"published-print":{"date-parts":[[1998,7]]}},"alternative-id":["10.1136\/jcp.51.7.502"],"URL":"https:\/\/doi.org\/10.1136\/jcp.51.7.502","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"type":"print","value":"0021-9746"},{"type":"electronic","value":"1472-4146"}],"subject":[],"published":{"date-parts":[[1998,7]]}}}